Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Olopatadine + mometasone is a fixed-dose combination nasal spray used for the treatment of seasonal allergic rhinitis (hay fever) and rhinoconjunctivitis in adults and adolescents aged 12 years and older. It contains two active ingredients: - Olopatadine, an antihistamine that blocks histamine H1 receptors to prevent symptoms such as itching, sneezing, runny nose, and watery eyes. - Mometasone furoate, a corticosteroid that reduces inflammation by inhibiting the release of substances involved in allergic reactions. The combination provides rapid relief (onset within 15 minutes) of both nasal and ocular allergy symptoms. It is administered as a metered-dose aqueous suspension via intranasal spray[1][2][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on olopatadine + mometasone.